Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Summary

The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).

Timeline

Start

2014-07

Primary completion

2018-05-23

Completion

2018-05-23

Outcome

Outcome not reported

Stopped (Enrollment): “did not meet target accrual”

Publications

• Sun ML, Dong JM, Liu C, Li P, Zhang C, Zhen J, Chen W. Metformin-mediated protection against doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2024 Nov;180:117535. doi: 10.1016/j.biopha.2024.117535. Epub 2024 Oct 15.

Drugs

Indications